Ferric carboxymaltose for iron deficiency in patients with heart failure: a systematic review and meta-analysis

Figures & data

Table 1. Search strategy.

Database	String	Results
PubMed	(“ferric carboxymaltose”[Supplementary Concept] OR “ferric carboxymaltose”[All Fields] OR “FCM”[All Fields] OR (“iron”[MeSH Terms] OR “iron”[All Fields])) AND (“heart failure”[MeSH Terms] OR (“heart”[All Fields] AND “failure”[All Fields]) OR “heart failure”[All Fields] OR (“heart failure”[MeSH Terms] OR (“heart”[All Fields] AND “failure”[All Fields]) OR “heart failure”[All Fields] OR (“cardiac”[All Fields] AND “failure”[All Fields]) OR “cardiac failure”[All Fields]) OR (“congest heart fail”[Journal] OR “chf”[All Fields]) OR “AHF”[All Fields])	2650
Scopus	((TITLE-ABS-KEY (ferric AND carboxymaltose) OR TITLE-ABS-KEY (fcm) OR TITLE-ABS-KEY (iron) )) AND ((TITLE-ABS-KEY (heart AND failure) OR TITLE-ABS-KEY (cardiac AND failure) OR TITLE-ABS-KEY (chf) OR TITLE-ABS-KEY (ahf) ))	6,251
Cochrane CENTRAL	(Ferric carboxymaltose OR FCM OR iron) AND (heart failure OR cardiac failure OR CHF OR AHF)	537

Figure 1. Prisma flow chart.

Table 2. Baseline Characteristics.

S No	Title	Trial title	Author	Year	Sample size	Gender		Ferric carboxymaltose						Placebo
						Male	Female	No. of patients	Male/female n	Mean age	LVEF %	ASA status (I/II/III/IV)	HB	No.of patients	Male/female n	Mean age	LVEF %	ASA status (I/II/III/IV)	HB
1	Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency	FAIR-HF	Anker, Stefan D et al.	2009	459	215	244	304	145/159	67.8	31.9	0/53/251/0	11.9	155	70/85	67.4	33.0	0/29/126/0	11.9
2	Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency†	CONFIRM-HF	Ponikowski, Piotr et al.	2015	301	160	141	150	83/67	68.8	37.1	0/80/7/0	12.37	151	77/74	68.5	36.5	0/91/61/0	12.42
3	Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial	AFFIRM-HF	Ponikowski, Piotr et al.	2020	1108	614	494	558	314/244	71.2	32.6	14/255/272/16	12.3	550	300/250	70.9	32.7	8/240/277/22	12.1
4	The effect of intravenous ferric carboxymaltose on cardiac reverse remodelling following cardiac resynchronization therapy	IRON-CRT	Pieter Martens et al.	2021	75	51	24	37	26/11	72	33	0/22/15/0	13.3	38	26/12	73	34	0/19/19/0	13.1
5	Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency	EFFECT-HF	Van Veldhuisen, Dirk J et al.	2017	172	129	43	86	60/26	63	33	0/61/25/0	12.9	86	69/17	64	31	0/54/32/0	13.0
6	Single-dose intravenous iron in Southeast Asian heart failure patients: A pilot randomized placebocontrolled study	PRACTICE-ASIA-HF	Tee Joo Yeo et al.	2018	49	38	11	24	18/6	61.1	38.8	N/A	11.6	25	20/5	64	33.2	N/A	13.1
7	Ferric Carboxymaltose in Heart Failure with Iron Deficiency	HEART-FID	Mentz, Robert J et al.	2023	3065	2028	1037	1532	1026/506	68.6	30.8	0/797/711/22	12.6	1533	1002/531	68.6	30.6	0/820/692/19	12.5

Figure 2. Quality assessment. (A) Risk of bias assessment; +indicates a low risk of bias; −indicates high risk of bias; ? indicate an unclear risk of bias. (B) Risk of bias graph, presented as percentages.

Figure 3. Summary of results.

Figure 4. Summary of results.

Figure 5. Summary of results.